Goldman Sachs analyst Chris Shibutani maintained a Buy rating on BioNTech SE (BNTX – Research Report) today and set a price target of $136.00.

In a report released today, Terence Flynn from Morgan Stanley maintained a Buy rating on BioNTech SE (BNTX – Research Report), with a price ...

Q4 2024 Earnings Call Transcript March 20, 2025 Autolus Therapeutics plc beats earnings expectations. Reported EPS is $-0.09, ...

U.S. commercial launch progressing on track with 33 authorized treatment centers as of March 19, 2025, following US FDA approval on November 8, 2024Obe-cel MHRA and EMA marketing authorizations ...

Truist Financial analyst Asthika Goonewardene maintained a Buy rating on Caribou Biosciences (CRBU – Research Report) today. The company’s ...

The White House is reportedly considering former U.S. Rep. Michael Burgess (R-Texas) as its nominee to head the CDC. Burgess, ...

Truist Financial analyst Asthika Goonewardene maintained a Buy rating on Genmab (GMAB – Research Report) today. The company’s shares closed ...

Autolus Therapeutics PLC (AUTL) reports significant cash reserves and strategic advancements despite increased operational expenses.

U.S. commercial launch progressing on track with 33 authorized treatment centers as of March 19, 2025, following US FDA approval on November 8, 2024Obe-cel MHRA and ...

The CDC has rescheduled a key advisory committee meeting on vaccine experts to April following a delay in February, a week ...

Apogee (NASDAQ:APOG), price target $95. Avidity, price target $70, BioNTech (NASDAQ:BNTX), price target $145. Kiniksa, 89BIO (ETNB) appears to have found support after losing some value lately ...